Pain Affecting Patents (Class 514/18.3)
  • Patent number: 10357533
    Abstract: The proposed drug relates to medicine and veterinary applications, in particular, as a means for effective control of acute and/or chronic pain, and may be used in emergency medicine for the treatment of acute and/or chronic pain, including the late stages of cancer. The stated means is based on a compound for preventing and/or treating acute or chronic pain in a subject, including an analgesic peptide having an amino acid sequence H-Tyr-D-Arg-Phe-Gly-NH2 or an amino acid sequence H-Tyr-D-Arg-Phe-Sar-OH. Also, a method of use/administration of the compound for the prevention and/or treatment of acute and/or chronic pain is disclosed.
    Type: Grant
    Filed: April 13, 2017
    Date of Patent: July 23, 2019
    Assignee: PVP LaBs PTE, Ltd.
    Inventors: Vyacheslav Stanislavovich Kosorukov, Evgeny Stanislavovic Rzhaninov, Nikolai Vasilievich Korobov
  • Patent number: 10227379
    Abstract: The present invention relates to tripeptide compounds according to the general formula (1) and their use as a medicament, in particular as anti-inflammatory agents.
    Type: Grant
    Filed: September 23, 2014
    Date of Patent: March 12, 2019
    Assignee: Dr. August Wolff Gmbh & Co. KG Arzneimittel
    Inventors: Michael Soeberdt, Ulrich Knie, Christoph Abels
  • Patent number: 9428483
    Abstract: Provided are a fluorine-containing amino acid prodrug represented by general formula (I) that makes a fluorine-containing amino acid which is a group 2 metabotropic glutamate receptor agonist into a prodrug, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 31, 2013
    Date of Patent: August 30, 2016
    Assignee: TAISHO PHARMACEUTICAL CO., LTD.
    Inventors: Takashi Hashihayata, Norikazu Otake, Naoki Miyakoshi, Kazunari Sakagami
  • Publication number: 20150140046
    Abstract: Compounds of general formula (I): R1-Wn-Xm-AA1-AA2-AA3-AA4-AA5-AA6-AA7-AA8-AA9-Yp-Zq-R2 (I) their stereoisomers, mixtures thereof and/or their cosmetically or pharmaceutically acceptable salts, preparation processes, cosmetic or pharmaceutical compositions which contain them and their use in medicine, particularly in the treatment and/or prevention of pain, inflammation, itching, neurological, compulsive and/or neuropsychiatric diseases and/or disorders and in processes of treatment and/or care of the skin, hair and/or mucous membranes mediated by neuronal exocytosis.
    Type: Application
    Filed: April 12, 2013
    Publication date: May 21, 2015
    Inventors: Antonio Vicente Ferrer Montiel, Gregorio Fernández Ballester, José María García Antón, Cristina Carreño Serraïma, Núria Almiñana Doménech, Raquel Delgado González
  • Patent number: 9034377
    Abstract: The present invention relates to a plurality of dosage forms comprising a first dosage form and second dosage form each comprising a therapeutic agent, such as an opioid; wherein the dosage strength of the second dosage form is greater than that of the first dosage form; and wherein the steady state Cave and the steady state AUC of the first and second dosage forms are dose proportional and the single dose Cmax of the second dosage form is less than the minimum level for dose proportionality with respect to the first dosage form. The present invention also relates to methods of administering such dosage forms to a patient, as well as to kits comprising such dosage forms and instructions for administration of the dosage forms to a patient. The inventors believe that the dosage forms and methods of the present invention will lead to improved safety and patient acceptance.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: May 19, 2015
    Assignee: Purdue Pharma, L.P.
    Inventors: Curtis Wright, Robert Colucci, Ahmed El-Tahtawy
  • Publication number: 20150132275
    Abstract: The present invention concerns a non-toxic solid pharmaceutical composition for oral administration, containing one or more cysteine compounds from the group of L-cysteine, D-cysteine and N-acetyl cysteine, combined with one or more additional active agents, at least one of which being selected from cystine, glutathione and methionine, the composition further containing one or more pharmaceutical additives. Further, the invention concerns a method for reducing the incidence of severe headaches, particularly migraine and/or cluster headaches.
    Type: Application
    Filed: May 28, 2013
    Publication date: May 14, 2015
    Applicant: BIOHIT OYJ
    Inventor: Osmo Suovaniemi
  • Patent number: 9018173
    Abstract: N-type voltage-gated calcium channels (CaV2.2) are critical mediators of neurotransmitter release and are thought to be involved with transmission of nociception. The use of conventional CaV2.2 blockers in pain therapeutics is limited by side effects. Reported herein is a means to suppress both inflammatory and neuropathic pain without directly blocking CaV2.2, but rather by inhibiting the binding of the axonal collapsin response mediator protein 2 (CRMP-2), a protein known to enhance CaV2.2 function. A 15 amino acid peptide of CRMP-2 fused to the protein transduction domain of the HIV tat protein (TAT CBD3) reduced meningeal blood flow induced by activation of the trigeminovascular system, prevented inflammation-induced tactile hypernociception induced by intraplantar formalin and nocifensive behavior following corneal capsaicin application, and reversed neuropathic hypernociception produced by the antiretroviral drug 2?,3?-dideoxycytidine. Preventing CRMP-2—mediated enhancement of CaV2.
    Type: Grant
    Filed: June 10, 2011
    Date of Patent: April 28, 2015
    Assignee: Indiana University Research and Technology Corp.
    Inventor: Rajesh Khanna
  • Publication number: 20150094265
    Abstract: The present invention features peptides, compositions, and related methods for treating gastrointestinal disorders and conditions, including but not limited to, irritable bowel syndrome (IBS), gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia, visceral pain, gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), disorders and conditions associated with constipation, and other conditions and disorders are described herein. using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.
    Type: Application
    Filed: December 1, 2014
    Publication date: April 2, 2015
    Inventors: ANGELIKA FRETZEN, HONG ZHAO, MARCO KESSLER
  • Publication number: 20150087596
    Abstract: The present invention relates to Huwentoxin-IV variants, polynucleotides encoding them, methods of making and using the foregoing, and methods of alleviating pain with peptide inhibitors of Nav1.7.
    Type: Application
    Filed: March 15, 2013
    Publication date: March 26, 2015
    Inventors: William Eckert, Mack Flinspach, Michael Hunter, Yi Liu, Robert Neff, Alan Wickenden, Alan Gibbs
  • Publication number: 20150080314
    Abstract: Ocular analgesics for topical administration are described. The topical ocular analgesic includes a neo-tryptophan-containing neurotensin analog. The topical ocular analgesic may alternatively include a buffered salt solution, a local anesthetic solution, a tissue penetrating agent, and/or an opiate. The neo-tryptophan-containing neurotensin analog may be present in a dose of about 0.0005 to about 1.2 mg.
    Type: Application
    Filed: April 4, 2014
    Publication date: March 19, 2015
    Applicants: Sarentis Therapeutics, Inc., Mayo Foundation for Medical Education and Research, Sloan-Kettering Institute for Cancer Research
    Inventors: DENISE BARBUT, Gavril W. Pasternak, Elliott Richelson
  • Patent number: 8980302
    Abstract: Surgical implants of the present disclosed include a film comprising a first therapeutic agent and a mesh comprising a second therapeutic agent. The surgical implant includes a film in direct contact with a mesh. The first therapeutic agent may be released at a first rate and the second therapeutic agent may be released at a second rate.
    Type: Grant
    Filed: May 12, 2014
    Date of Patent: March 17, 2015
    Assignee: Covidien LP
    Inventors: Joshua Stopek, Amin Elachchabi, Daniel Broom, Garrett Ebersole
  • Publication number: 20150023988
    Abstract: Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted Nav1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of Nav1.7. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic acids encoding some embodiments of inventive polypeptides and expression vectors, and recombinant host cells containing them are disclosed. A method of treating or preventing pain is also disclosed.
    Type: Application
    Filed: March 12, 2014
    Publication date: January 22, 2015
    Applicant: AMGEN INC.
    Inventors: Justin K. MURRAY, Jerry Ryan HOLDER, Malgorzata WANSKA, Christopher M. TEGLEY, James R. FALSEY, Elizabeth M. DOHERTY, Leslie P. MIRANDA
  • Publication number: 20150018283
    Abstract: The invention provides agents useful for treating pain. An exemplary agent comprises or consists of the a portion of a retroviral Tat protein. One such agent is the peptide Tat-NR2B9c. This peptide has previously been described as an agent for inhibiting damaging effects of stroke and similar conditions via inhibition of PSD95 interactions with NMDA receptors and/or NOS. The present application provides data showing that the Tat-NR2B9c peptides is effective in alleviation of pain. The alleviation of pain can be obtained at a dose of the peptide below the dose required to inhibit PSD-95 interactions with NMDAR or NOS.
    Type: Application
    Filed: May 9, 2014
    Publication date: January 15, 2015
    Applicant: NoNO NC.
    Inventors: Michael P. Belmares, Jonathan David Garman, Peter S. Lu, Michael W. Salter, Michael Tymianski
  • Patent number: 8933020
    Abstract: Disclosed are compositions and methods related to improving pharmacological properties of bioactive compounds targeting nervous system.
    Type: Grant
    Filed: March 29, 2013
    Date of Patent: January 13, 2015
    Assignee: University of Utah Research Foundation
    Inventors: Grzegorz Bulaj, H. Steve White
  • Patent number: 8921322
    Abstract: The present invention relates to the use of at least one botulinum neurotoxin for the production of a medicament for treating or preventing pain induced by a medicament used for treating the AIDS virus.
    Type: Grant
    Filed: December 17, 2007
    Date of Patent: December 30, 2014
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Christine Favre, Michel Auguet, Pierre-Etienne Chabrier De Lassauniere
  • Patent number: 8921305
    Abstract: Disclosed is a method for treating cancer and/or pain using an intra-patient dose escalation procedure to deliver dosages of crotoxin.
    Type: Grant
    Filed: January 22, 2013
    Date of Patent: December 30, 2014
    Assignee: Celtic Biotech Iowa, Inc.
    Inventor: Paul F. Reid
  • Publication number: 20140371153
    Abstract: The present invention is directed to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl 1, buprenorphine, and sufentanil, or its pharmaceutically acceptable salts thereof, wherein the ?-conopeptide retains its potency and is physically and chemically compatible with the analgesic compound. A preferred route of administration is intrathecal administration, particularly continuous intrathecal infusion. The present invention is also directed to a pharmaceutical formulation comprising an omega conopeptide, preferably ziconotide, an antioxidant, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl, buprenorphine, and sufentanil.
    Type: Application
    Filed: June 20, 2014
    Publication date: December 18, 2014
    Inventors: David J. ELLIS, George P. Miljanich, David E. Shields
  • Publication number: 20140342989
    Abstract: A first aspect of the invention is a compound (sometimes also referred to herein as an “active agent” or “active compound”) of Formula Ia, or more particularly Formula Ib: or a pharmaceutically acceptable salt or prodrug thereof. Compositions thereof and methods of using the same (e.g. for the treatment of a neurological disease) are also described.
    Type: Application
    Filed: July 31, 2014
    Publication date: November 20, 2014
    Inventors: Harold L. Kohn, Christophe Salome, Elise Salome-Grosjean
  • Patent number: 8889827
    Abstract: The present invention relates to modified opiorphin peptides as new inhibitors of metallo-ectopeptidases.
    Type: Grant
    Filed: April 7, 2009
    Date of Patent: November 18, 2014
    Assignee: Institut Pasteur
    Inventor: Catherine Rougeot
  • Patent number: 8877225
    Abstract: The present invention provides a constant release copolymer composition adapted for use in a controlled release formulation for a bioactive agent, such as a formulation adapted for implantation within a patient's body tissues as a depot to release the agent over a period of time, wherein the copolymer provides a substantially constant rate of release of the bioactive agent over the time period for which the depot persists in the body tissues. The copolymer includes a PLG copolymer and a PLG oligomer of about 5-10 kDa average molecular weight, which can lack free carboxylic acid groups. When the PLG copolymer is a low burst copolymer, the constant release copolymer composition is a low burst, constant release copolymer composition adapted for implantation in the body tissues of a mammal, wherein a substantially constant rate of release of the bioactive agent is achieved.
    Type: Grant
    Filed: June 3, 2009
    Date of Patent: November 4, 2014
    Assignee: Tolmar Therapeutics, Inc.
    Inventors: Richard L. Norton, Eric Dadey
  • Patent number: 8877891
    Abstract: The use of opioid peptides of a novel structure is claimed which, in addition to a pharmacophore, additionally contain structural elements reactive with tachykinin receptors. Due to the synergistic reactivity of the opioid with an additional element, an increased analgesic activity is obtained facilitating protracted effective use due to decreased drug tolerance effects. The drugs may particularly be of use in the treatment of chronic pain as effective analgesics during inflammation caused by rheumatism, gout, neurodegenerative states, post-surgical and post-traumatic inflammations or ones induced by tumors.
    Type: Grant
    Filed: June 30, 2011
    Date of Patent: November 4, 2014
    Inventor: Andrej Lipkowski
  • Publication number: 20140322132
    Abstract: Provided are fragments of human p97 (melanotransferrin) polypeptides having blood-brain barrier (BBB) transport activity, including variants and combinations thereof, conjugates comprising said p97 fragments, and related methods of use thereof, for instance, to facilitate delivery of therapeutic or diagnostic agents across the BBB.
    Type: Application
    Filed: March 13, 2014
    Publication date: October 30, 2014
    Inventors: Timothy Z. Vitalis, Reinhard Gabathuler
  • Patent number: 8859505
    Abstract: Compounds of the formula I wherein R2a and R2b are independently H, halo, C1-C4alkyl, C1-C4haloalkyl or C1-C4alkoxy, or R2a and R2b together with the carbon atom to which they are attached form a C3-C6cycloalkyl; R3 is a C5-C10 alkyl, optionally substituted with 1-3 substituents independently selected from halo, C1-C4haloalkyl, C1-C4alkoxy, C1-C4haloalkoxy; or R3 is a C2-C4alkyl chain with at least 2 chloro or 3 fluoro substituents; or R3 is C3-C7cycloalkylmethyl, optionally substituted with 1-3 substituents independently selected from C1-C4alkyl, halo, C1-C4haloalkyl, C1-C4alkoxy, C1-C4haloalkoxy; R4 is C1-C6alkyl, C1-C6haloalkyl, C1-C6alkoxy, C1-C6haloalkoxy, C1-C6alkylamino, C1-C6dialkylamino or; R4 is Het or Carbocyclyl, either of which is optionally substituted with 1-3 substituents R4 is Het, carbocyclyl, C1-C6alkyl, C1-C6haloalkyl, C1-C6alkoxy or C1-C6haloalkoxy; n is 1, 2 or 3; for the use in the prophylaxis or treatment of a disorder characterised by inappropriate expression or activation of ca
    Type: Grant
    Filed: June 16, 2011
    Date of Patent: October 14, 2014
    Assignee: Medivir UK Ltd
    Inventors: Susana Ayesa, Urszula Grabowska, Ellen Hewitt, Daniel Jonsson, Bjorn Klasson, Pia Kahnberg, Stina Lundgren, Jan Tejbrant, Daniel Wiktelius
  • Patent number: 8859500
    Abstract: The present invention provides a method for ameliorating inflammatory and/or neuropathic pain in a subject by modifying the activity of N-methyl-D-aspartate (NMDA) receptors in cells of the subject by inhibition of the interaction of the unique domain of the tyrosine kinase Src enzyme and the NMDA receptor complex.
    Type: Grant
    Filed: March 21, 2012
    Date of Patent: October 14, 2014
    Assignee: The Hospital For Sick Children
    Inventors: Michael W. Salter, Jeffrey R. Gingrich
  • Publication number: 20140303080
    Abstract: N-acyldipeptide derivatives are described. Compositions comprising the N-acyldipeptide derivatives are therapeutically effective for topical or systemic administration to alleviate or improve conditions, disorders, diseases, symptoms or syndromes associated with a tumor, cancer, immune, nervous, vascular, musculoskeletal or cutaneous system, or other tissue or system in a subject.
    Type: Application
    Filed: October 31, 2012
    Publication date: October 9, 2014
    Inventors: Ruey J. Yu, Eugene J. Van Scott
  • Patent number: 8853359
    Abstract: The present invention provides peptides capable of sustaining antagonist activity against substance P for long periods of time. A peptide selected from (a) to (d) can sustain antagonist activity against substance P, analgesic activity, and anti-inflammation activity for a long period of time: (SEQ ID NO: 3) (a)?Ala-Tyr-Gln-Leu-Glu-His-Thr-DTrp-Gln-Gly-Leu- Leu-NH2; (b) a peptide consisting of a partial sequence of (a), which consists of 6 to 11 consecutive amino acids comprising at least the C-terminal Thr-DTrp-Gln-Gly-Leu-Leu-NH2 (SEQ ID NO: 18); (c) Ala-Tyr-Gln-Leu-Glu-His-Thr-Phe-Gln-DTrp-Leu-Leu-NH2 (SEQ ID NO: 4); and (d) a peptide consisting of a partial sequence of (c), which consists of 6 to 11 consecutive amino acids comprising at least the C-terminal Thr-Phe-Gln-DTrp-Leu-Leu-NH2 (SEQ ID NO: 8).
    Type: Grant
    Filed: May 31, 2010
    Date of Patent: October 7, 2014
    Assignee: University of Miyazaki
    Inventors: Toshikazu Nishimori, Rumi Naono
  • Patent number: 8846622
    Abstract: Botulinum toxin, among other presynaptic neurotoxins is used for the treatment and prevention of migraine and other headaches associated with vascular disorders. Presynaptic neurotoxins are delivered focally, targeting the sphenopalatine ganglion. Exemplary delivery is carried out by way of injection.
    Type: Grant
    Filed: August 15, 2013
    Date of Patent: September 30, 2014
    Assignee: Allergan, Inc.
    Inventor: Andrew M. Blumenfeld
  • Publication number: 20140287986
    Abstract: Novel template-fixed ?-hairpin peptidomimetics of the general formula (I): cyclo[P1-P2-P3-P4-P5-P6-P7-P8-P9-P10-P11-P12-P13-P14-T1-T2] wherein the single elements T or P are ?-amino acid residues connected in either direction which, depending on their positions in the chain, are as defined in the description and the claims, and salts thereof, have the property of antagonizing the biological effect of the receptor FPR1. They can be used as medicaments to treat or prevent diseases or conditions in the areas of inflammatory diseases, allergic conditions, immunological disorders, neuroinflammation, neurological disorders, obstructive airway diseases, infectious diseases, ischemic reperfusion injuries and proliferative disorders such as e.g. cancer. These ?-hairpin peptidomimetics can be manufactured by a process which is based on a mixed solid- and solution phase synthetic strategy.
    Type: Application
    Filed: October 2, 2012
    Publication date: September 25, 2014
    Applicant: POLYPHOR AG
    Inventors: Françoise Jun, Danie Obrecht, Ralf Löwe, Johann Zimmermann, Guillaume Lemercier, Eric Chevalier
  • Patent number: 8835377
    Abstract: Bioavailability of peptide active agents to be administered orally is enhanced by a pharmaceutical composition providing targeted release of the peptide to the intestine by combining the composition with an absorption enhancer. Bioavailability is further significantly increased by administering the composition in an acid-resistant protective vehicle which transports components of the invention through the stomach. The composition may optionally further include a sufficient amount of a pH-lowering agent to lower local intestinal pH. All components are released together into the intestine with the peptide.
    Type: Grant
    Filed: August 26, 2011
    Date of Patent: September 16, 2014
    Assignee: UGP Therapeutics, Inc.
    Inventors: Nozer M. Mehta, William Stern, James P. Gilligan
  • Publication number: 20140255487
    Abstract: Oral dosage forms as a biodegradable, water soluble film for delivering pharmaceutically active agents, to patients through insertion into the mouth of patient and methods for administering pharmaceutically active agents to patients by insertion into the mouth to provide selective uptake of said agents through the mucosa and thus avoiding the gastrointestinal tract.
    Type: Application
    Filed: May 16, 2014
    Publication date: September 11, 2014
    Applicant: NAL Pharmaceuticals Ltd.
    Inventors: Je Phil Ryoo, Chun Kwong Chu, Zheng Wang
  • Patent number: 8815810
    Abstract: The present invention relates to the use of Meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain. In a preferred embodiment the disorder to be treated is allodynia, and hyperalgesia, more preferably allodynia including thermal and tactile allodynia.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: August 26, 2014
    Assignee: NsGene A/S
    Inventors: Jesper Roland Jørgensen, Lars Ulrik Wahlberg, Teit E. Johansen
  • Patent number: 8815809
    Abstract: Compounds of Formula II wherein R1a is H; and R1b is C1-C6alkyl, Carbocyclyl or Het; or R1a and R1b together define a saturated cyclic amine with 3-6 ring atoms; R2a and R2b are independently H, halo, C1-C4alkyl, C1-C4haloalkyl or C1-C4alkoxy, or R2a and R2b together with the carbon atom to which they are attached form a C3-C6cycloalkyl; R3 is a branched C5-C10 alkyl chain, C2-C4haloalkyl or —CH2C3-C7 cycloalkyl; R4? is C1-C6alkyl, C1-C6haloalkyl or oxetany-3-yl. for use in the prophylaxis or treatment of a disorder characterized by inappropriate expression or activation of cathepsin S.
    Type: Grant
    Filed: December 10, 2010
    Date of Patent: August 26, 2014
    Assignee: Medivir UK Ltd
    Inventors: Susana Ayesa, Karolina Ersmark, Urszula Grabowska, Ellen Hewitt, Daniel Jönsson, Pia Kahnberg, Björn Klasson, Peter Lind, Stina Lundgren, Lourdes Odèn, Kevin Parkes, Daniel Wiktelius
  • Publication number: 20140194364
    Abstract: The present disclosure provides methods of diagnosing painful intervertebral discs. The present disclosure also provides methods of treating a painful intervertebral disc.
    Type: Application
    Filed: December 11, 2013
    Publication date: July 10, 2014
    Applicant: The Regents of the University of California
    Inventors: Zorica Buser, Jeffrey Charles Lotz
  • Publication number: 20140193466
    Abstract: The present invention provides for silk-derived compositions for treating a wide variety of ocular conditions. The composition is produced by processing the silk cocoon into a water-based solution (i.e., a dissolved silk), which is then cast into a film. The film may be transparent to visible light, and curved in shape for easy application to the ocular surface. The silk film may either self-adhere or be sutured to cover the wound. The degradation time of the film may range from 1 minute to 24 hours, or from 2 hours to 20 hours. The present compositions can help regenerate damaged corneal tissue, thus promoting healing.
    Type: Application
    Filed: June 7, 2012
    Publication date: July 10, 2014
    Applicant: CORNELL UNIVERSITY
    Inventors: Brian D Lawrence, Alejandro Navas, Mark I. Rosenblatt
  • Patent number: 8765677
    Abstract: This invention relates to an isolated, synthetic or recombinant peptide, wherein the peptide comprises the sequence: C K G K G A Xaa1 C R Xaa2 Xaa3 Xaa4 Y Xaa5 C C Xaa6 G Xaa7 C R Xaa8 Xaa9 R C SEQ ID NO: 1 wherein Xaa1, Xaa3, Xaa4, Xaa6, Xaa7 and Xaa8 are independently selected from serine and threonine; Xaa2 is selected from arginine and lysine; Xaa5 is selected from aspartic acid and glutamic acid; and Xaa9 is selected from glycine, alanine, valine, leucine and isoleucine.
    Type: Grant
    Filed: September 21, 2010
    Date of Patent: July 1, 2014
    Assignees: The University of Queensland, The University of Sydney
    Inventors: Richard Lewis, David John Adams, Geza Berecki, Roger Drinkwater, Paul Francis Alewood, MacDonald James Christie
  • Patent number: 8765680
    Abstract: The present invention is directed to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl 1, buprenorphine, and sufentanil, or its pharmaceutically acceptable salts thereof, wherein the ?-conopeptide retains its potency and is physically and chemically compatible with the analgesic compound. A preferred route of administration is intrathecal administration, particularly continuous intrathecal infusion. The present invention is also directed to a pharmaceutical formulation comprising an omega conopeptide, preferably ziconotide, an antioxidant, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl, buprenorphine, and sufentanil.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: July 1, 2014
    Assignee: Jazz Pharmaceuticals International Limited
    Inventors: David J. Ellis, George P. Miljanich, David E. Shields
  • Publication number: 20140178381
    Abstract: Transport peptides, alone or attached to a cargo moiety, are capable of targeted axonal import into the spinal cord and other structures of the central nervous system. The transport peptides can be used to deliver therapeutic agents and other molecules of interest from the periphery to the central nervous system, providing a means to detect, treat or prevent neurodegenerative diseases, stroke, chronic pain and other conditions via minimally invasive techniques of administration.
    Type: Application
    Filed: September 8, 2012
    Publication date: June 26, 2014
    Applicant: UNIVERSITY OF WASHINGTON
    Inventors: Suzie H. Pun, Drew L. Sellers, Jamie M. Bergen, Philip J. Horner
  • Publication number: 20140179615
    Abstract: A pharmaceutical composition of glutathione and acetaminophen and preparation method thereof. The active ingredients of the composition include glutathione with composition ration of 0.1%˜99.9% and acetaminophen with composition ratio of 99.9%˜0.1%. The further purpose of the invention is to prepare glutathione and acetaminophen composition (raw materials) into various pharmaceutically acceptable dosage forms, such as tablets, sustained/controlled release preparations, capsules, pills, syrups, films, granules, oral solutions, oral suspensions, oral emulsions and oral powders. The beneficial effects of the invention is reflected in that glutathione and acetaminophen combination can effectively prevent the liver cell damage and necrosis caused by acetaminophen overdose and is strongly in favor of cancer pain relief and chemotherapy.
    Type: Application
    Filed: June 12, 2012
    Publication date: June 26, 2014
    Inventors: Liuyi Wang, Jincan Wang
  • Patent number: 8758800
    Abstract: Surgical implants are provided which include a film comprising a first therapeutic agent and a mesh comprising a second therapeutic agent. The surgical implant includes a film in direct contact with a mesh. The first therapeutic agent may be released at a first rate and the second therapeutic agent may be released at a second rate.
    Type: Grant
    Filed: March 18, 2011
    Date of Patent: June 24, 2014
    Assignee: Covidien LP
    Inventors: Joshua Stopek, Amin Elachchabi, Daniel Broom, Garrett Ebersole
  • Patent number: 8758799
    Abstract: Surgical implants are provided which include a film comprising a first therapeutic agent and a mesh comprising a second therapeutic agent. The surgical implant includes a film in direct contact with a mesh. The first therapeutic agent may be released at a first rate and the second therapeutic agent may be released at a second rate.
    Type: Grant
    Filed: March 18, 2011
    Date of Patent: June 24, 2014
    Assignee: Covidien LP
    Inventors: Joshua Stopek, Amin Elachchabi, Daniel Broom, Garrett Ebersole
  • Patent number: 8758798
    Abstract: Surgical implants are provided which include a film comprising a first therapeutic agent and a mesh comprising a second therapeutic agent. The surgical implant includes a film in direct contact with a mesh. The first therapeutic agent may be released at a first rate and the second therapeutic agent may be released at a second rate.
    Type: Grant
    Filed: March 18, 2011
    Date of Patent: June 24, 2014
    Assignee: Covidien LP
    Inventors: Joshua Stopek, Amin Elachchabi, Daniel Broom, Garrett Ebersole
  • Patent number: 8754036
    Abstract: An object of the present invention is to provide a substance which is able to be an active ingredient for the improvement of dysfunction caused by nerve damage. An improving agent for dysfunction due to nerve damage of the present invention as a means for resolution thereof is characterized in that it comprises an endo-?-N-acetylglucosaminidase type enzyme which hydrolyzes an N-acetylglucosamide bond in a keratan sulfate backbone as an active ingredient. When the improving agent of the present invention is administered, clinical improvement is achieved in motor neuron dysfunction and sensory neuron dysfunction such as neuropathic pain represented by a pain caused by allodynia and hyperalgesic reaction of the object to be treated.
    Type: Grant
    Filed: February 27, 2013
    Date of Patent: June 17, 2014
    Assignees: National University Corporation Nagoya University, Seikagaku Corporation
    Inventors: Kenji Kadomatsu, Yukihiro Matsuyama, Akiomi Tanaka, Sawako Takeshita
  • Patent number: 8754037
    Abstract: Provided is a modified human tumor necrosis factor receptor-1 polypeptide or a fragment thereof that binds to a tumor necrosis factor in vivo or ex vivo. The modified human tumor necrosis factor receptor-1 polypeptide or fragment exhibits improved ability to bind tumor necrosis factor and resistance to proteases.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: June 17, 2014
    Assignee: Hanall Biopharma Co., Ltd.
    Inventors: Sung Wuk Kim, Sung Soo Jun, Seung Kook Park, Song Young Kim, Eun Sun Kim, Jae Kap Jeong, Ha Na Kim, Yeon Jung Song
  • Patent number: 8748384
    Abstract: The present invention provides agents for inhibiting binding of a pro-neurotrophin to a Vps1 Op-domain receptor, in particular the binding of a pro-NGF or a pro-BDNF to a Sortilin receptor. The invention thus provides agents for the manufacture of a medicament, for treating and/or preventing disease or disorders such as but not limited to neurological, neuropsychiatric and ocular diseases, disorders, and degeneration as well as obesity, diabetes, pain and/or nociception in an individual.
    Type: Grant
    Filed: December 21, 2007
    Date of Patent: June 10, 2014
    Assignee: H. Lundbeck A/S
    Inventors: Olav Michael Andersen, Anders Nykjaer
  • Patent number: 8748387
    Abstract: The invention provides agents useful for treating pain. An exemplary agent comprises or consists of the a portion of a retroviral Tat protein. One such agent is the peptide Tat-NR2B9c. This peptide has previously been described as an agent for inhibiting damaging effects of stroke and similar conditions via inhibition of PSD95 interactions with NMDA receptors and/or NOS. The present application provides data showing that the Tat-NR2B9c peptides is effective in alleviation of pain. The alleviation of pain can be obtained at a dose of the peptide below the dose required to inhibit PSD-95 interactions with NMDAR or NOS.
    Type: Grant
    Filed: November 13, 2012
    Date of Patent: June 10, 2014
    Assignee: NoNO Inc.
    Inventors: Michael P. Belmares, Jonathan David Garman, Peter S. Lu, Michael W. Salter, Michael Tymianski
  • Patent number: 8729027
    Abstract: Disclosed is a drug effective in the treatment of fibromyalgia. Basically, the disclosed therapeutic agent was created on the basis of experiments showing improvement in symptoms when etanercept was administered to patients suffering from fibromyalgia. Etanercept is known as a therapeutic agent for rheumatoid arthritis, and the JFIQ score of patients not suffering from fibromyalgia improved considerably in the preferred embodiment. In other words, a therapeutic agent for fibromyalgia is disclosed that contains etanercept as an active ingredient in an effective amount.
    Type: Grant
    Filed: July 4, 2011
    Date of Patent: May 20, 2014
    Assignee: AXIS Inc.
    Inventor: Kusuki Nishioka
  • Patent number: 8716436
    Abstract: The invention relates to cyclic peptide agonists that bind to the mu (morphine) opioid receptor and their use in the treatment of acute and/or chronic pain. Embodiments of the invention are directed to cyclic pentapeptide and hexapeptide analogs of endomorphin that have (i) a carboxy-terminal extension with an amidated hydrophilic amino acid and (ii) a substitution in amino acid position 2. These peptide analogs exhibit decreased tolerance relative to morphine, increased solubility compared to similar tetrapeptide analogs, while maintaining favorable or improved therapeutic ratios of analgesia to side effects.
    Type: Grant
    Filed: May 22, 2012
    Date of Patent: May 6, 2014
    Assignees: The Administrators of the Tulane Educational Fund, U.S. Department of Veterans Affairs
    Inventors: James E. Zadina, Laszlo Hackler
  • Publication number: 20140121168
    Abstract: TRPV1 antagonists and associated methods are provided. A TRPV1 channel antagonist can have the structure: Formula (I) wherein R1 can be —CH3, —(CH2)X(CH)YCH3 where x+y=1-20, an aromatic, a (CH2)n aromatic where n can be less than or equal to 6, a lipid, or a linker, and wherein R2 can be either Formula (II) or Formula (III) Additionally, R3 can be —O—R4 or —NH—R4 and R4 can be —H, —CH3, an ester, a cyclic ester, or an amide.
    Type: Application
    Filed: April 26, 2012
    Publication date: May 1, 2014
    Applicant: ANTAGONISTS OF TRPV1 RECEPTOR
    Inventors: Eric Schmidt, Alan R. Light, Baldomero M. Olivera, Christopher A. Reilly, Zhejian Lin, Gisela P. Concepcion
  • Publication number: 20140107038
    Abstract: The present invention is directed to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl 1, buprenorphine, and sufentanil, or its pharmaceutically acceptable salts thereof, wherein the ?-conopeptide retains its potency and is physically and chemically compatible with the analgesic compound. A preferred route of administration is intrathecal administration, particularly continuous intrathecal infusion. The present invention is also directed to a pharmaceutical formulation comprising an omega conopeptide, preferably ziconotide, an antioxidant, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl, buprenorphine, and sufentanil.
    Type: Application
    Filed: December 18, 2013
    Publication date: April 17, 2014
    Applicant: Jazz Pharmaceuticals International Limited
    Inventors: David J. ELLIS, George P. MILJANICH, David E. SHIELDS
  • Patent number: 8691764
    Abstract: The present invention provides a method for inhibiting NF-?B activity in a subject, the method comprising providing an agent capable of inducing expression of annexin 1, whereby said agent induces expression of annexin 1 and whereby said induced expression of annexin 1 inhibits NF-?B activity. Also provided are annexin 1 mimetics capable of binding to NF-?B and pharmaceutical compositions of such inducing and mimetic agents.
    Type: Grant
    Filed: March 28, 2008
    Date of Patent: April 8, 2014
    Assignee: The Research Foundation for the State University of New York
    Inventors: Zhiquan Zhang, Basil Rigas